Below are the press releases for EAS Congress 2024.
| Press release # | Embargoed until |
| PR#01-2024 EAS 2024 – Congress Highlights What will make the news? | Available for immediate release |
| PR#02-2024 Good discrimination between FH and non-FH by LDL-c levels in children 1-12 years Late breaker session 1: From molecular biology of the arterial wall to epidemiology of ASCVD, Monday May 27, 2024, @15:45 CET Presentation: Levels of LDL-cholesterol in newborns and children from 1-12 year old with genetically verified familial hypercholesterolemia; implications for cholesterol screening Presenting author: Martin Bogsrud. | May 27, 2024, 15:45 CET |
| PR#03-2024 Population-based genetic analysis sheds light on relationship between Lp(a) and CKD Late breaker session 1: From molecular biology of the arterial wall to epidemiology of ASCVD, Monday May 27, 2024, @15:45 CET Presentation: High lipoprotein(a) as a cause of chronic kidney disease: a population-based Mendelian randomization study Presenting author: Anne Langsted. | May 27, 2024, 15:45 CET |
| PR#04-2024 Novel third-generation PCSK9 inhibitor cuts LDL-c levels by 62% in patients with or at very high risk of ASCVD Late Breaker session 2: New therapeutic agents, Wednesday May 29, 2024, @11:00 CET Presentation: Long term efficacy and safety of lerodalcibep in patients with atherosclerotic cardiovascular disease (LIBERATE-CVD) Presenting author: Evan Stein. | May 29, 2024, 11:00 CET |
| PR#05-2024 Zodasiran reduces triglycerides and LDL-c in mixed dyslipidaemia Late Breaker session 2: New therapeutic agents, Wednesday May 29, 2024, @11:00 CET Presentation: Zodasiran silences hepatic angptl3 leading to deep and durable reductions in atherogenic lipids and lipoproteins in mixed dyslipidemia patients: final results from arches-2, double-blind period Presenting author: Robert Rosenson. | May 29, 2024, 11:00 CET |
| PR#06-2024 on behalf of AstraZeneca Oral PCSK9 inhibitor shows promise in lowering LDL-c Late Breaker session 2: New therapeutic agents, Wednesday May 29, 2024, @08:00 CET Presentation: AZD0780, the first oral small molecule PCSK9 inhibitor for the treatment of hypercholesterolemia: results from a randomized, single-blind, placebo-controlled phase 1 trial Presenting author: Rick Vega. | May 29, 2024, 08:00 CET |
Contact
Mateusz Szwachta
Email: mateusz@eas-society.org
